{"denoms":[{"counts":[{"groupId":"BG000","value":"436"},{"groupId":"BG001","value":"189"},{"groupId":"BG002","value":"48"},{"groupId":"BG003","value":"37"},{"groupId":"BG004","value":"710"}],"units":"Participants"}],"groups":[{"description":"Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for standard risk patients\n\nPFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.","id":"BG000","title":"Auto-Auto Standard Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients","id":"BG001","title":"Auto-Allo Standard Risk"},{"description":"Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for high risk patients\n\nPFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.","id":"BG002","title":"Auto-Auto High Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients","id":"BG003","title":"Auto-Allo High Risk"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"22","upperLimit":"70","value":"55"},{"groupId":"BG001","lowerLimit":"29","upperLimit":"68","value":"53"},{"groupId":"BG002","lowerLimit":"32","upperLimit":"70","value":"57"},{"groupId":"BG003","lowerLimit":"32","upperLimit":"66","value":"51"},{"groupId":"BG004","lowerLimit":"22","upperLimit":"68","value":"53.2"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"78"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"291"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"260"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"419"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"106"}]}],"title":"African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"335"},{"groupId":"BG001","value":"161"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"33"},{"groupId":"BG004","value":"567"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"37"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"344"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"545"}]}],"title":"100 - 90"},{"categories":[{"measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"165"}]}],"title":"< 90"}],"description":"Assesses patient self-perceived global quality of life and functioning (excellent, very good, good, fair, poor), where 100 equals perfect quality of life.","paramType":"NUMBER","title":"Karnofsky Performance score","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.004","upperLimit":"4.0","value":"2.0"},{"groupId":"BG001","lowerLimit":"0.9","upperLimit":"4.0","value":"2.0"},{"groupId":"BG002","lowerLimit":"0.9","upperLimit":"9.8","value":"4.4"},{"groupId":"BG003","lowerLimit":"1.2","upperLimit":"6.6","value":"3.7"},{"groupId":"BG004","lowerLimit":"0.004","upperLimit":"9.8","value":"3.025"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"β-2 Microglobulin","unitOfMeasure":"mg/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"142"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"220"}]}],"title":"Stages I-II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"294"},{"groupId":"BG001","value":"130"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"490"}]}],"title":"Stage III"}],"description":"The Durie and Salmon classification uses three multiple myeloma stages. Stage I has all of the following: Hemoglobin greater than 10 g/dL, Serum calcium less than 12 mg/dL, Normal bone structure or solitary plasmacytoma on radiographs, and Low M component. Stage II does not fit either Stage I or Stage III. Stage III has one or more of the following: Hemoglobin less than 8.5 g/dL, Serum calcium greater than 12 mg/dL, Advanced lytic bone lesions, and/or Hyper M component.","paramType":"NUMBER","title":"Durie-Salmon","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"3","upperLimit":"55","value":"7"},{"groupId":"BG001","lowerLimit":"4","upperLimit":"35","value":"7"},{"groupId":"BG002","lowerLimit":"5","upperLimit":"22","value":"7"},{"groupId":"BG003","lowerLimit":"3","upperLimit":"38","value":"7"},{"groupId":"BG004","lowerLimit":"3","upperLimit":"55","value":"7"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Interval from diagnosis to transplantation","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"69"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"90"}]}],"title":"Near CR"},{"categories":[{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"119"}]}],"title":"Very Good PR"},{"categories":[{"measurements":[{"groupId":"BG000","value":"158"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"269"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"61"}]}],"title":"MR"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"37"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"54"}]}],"title":"Not Evaluable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"11"}]}],"title":"Unknown"}],"description":"Disease status at time of first autologous transplantation represents the results from initial multiple myeloma therapy received prior to trial enrollment: Complete Response (CR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD)","paramType":"NUMBER","title":"Disease status","unitOfMeasure":"participants"}],"populationDescription":"Analysis is based on intention-to-treat data. Primary analysis of the clinical trial focused on patients meeting protocol criteria of standard risk multiple myeloma."}